About Delta Diagnostics

Meet The Team That’s Making A Difference.

The company Delta Diagnostics was founded in 2018 as a spin-off from TNO – The Netherlands Organisation for Applied Scientific Research. It commercializes the patented biosensor technology that has been developed at the Optics department of TNO.

We believe that the availability of our rapid, sensitive and low-cost biosensors and instruments will lead to new discoveries in Life Sciences, and ultimately to novel diagnostics that rely on accurate concentration measurement of a panel of biomarkers within minutes.

Since its founding, the company has grown steadily towards the highly-experienced and well-balanced team this is currently involved. During this time, it has worked hard to perfect its biosensing technology and prepare for the launch of its first product.

Partners.

That Support Delta Diagnostics’ Growth.

Co-Funded by the Horizon 2020 Programme of the European Union

Delta Diagnostics’ History

Through our historical narrative, we aim to inspire trust and collaboration among our partners in academia and the pharmaceutical industry, ensuring that we continue to make advanced research on biomolecular interactions accessible to all.

Foundation - March 2018

Foundation in march 2018 as a spin-off of TNO- The Netherlands Organisation for Applied Scientific Research to bring a versatile biosensing platform to the market that has resulted from almost a decade of solid TNO research. 

NWO Take-Off Grant - April 2018

In April 2018, Delta Diagnostics received an NWO grant to develop its business case (NWO Take-Off 1) 

Rotterdam Science Tower - November 2018

In November 2018, Delta Diagnostics moved to the Erasmus MC incubator facilities in the Rotterdam Science Tower, with its offices and an ML2 laboratory. Delta Diagnostics has access to a state-of-the-art photonics lab at TNO for instrument assembly and alignment.

NWO Take-Off Loan - December 2018

In December 2018, Delta Diagnostics received an NWO take-off loan of 250.000 for developing its instrument for Biomolecular Interaction Analysis.

SME Instrument Phase 1 Granted - March 2019

In March 2019, Delta Diagnostics was granted the SME instrument phase 1 subsidy to further develop its business case focussing on diagnostics.

 

First Prototype Presentation - November 2019

In November 2019, Delta Diagnostics presents one of its early prototype analysers at the Teknowledgy – NWO Innovation Festival fare .

 

Selection Fastlane Project - January 2020

In January 2020, Delta Diagnostics was one of 15 high-potential companies selected by The Netherlands Enterprise Agency RVO for its RVO Fastlane project. As part of this project, Delta Diagnostics receives support in the form of specialized advice from RVO in various strategic areas.

 

Investment Uniiq - January 2020

In January 2020, proof-of-concept fund Uniiq invests 200.000 in Delta Diagnostics enabling its further technology validation in preparation for a Series-A investment round.

First prototype delivered - May 2021

In April 2021, Delta Diagnostics delivered its first prototype R&D instrument to the NanoBio Research Group of Saxion Hogeschool. The instrument is, a.o., used in projects aimed to detect SARS-CoV-2 antigens and residues of several types of antibiotics in milk in the RAAK-MKB project PhoBioSens. Since then, several prototypes have been delivered to various partners.

MIT R&D Grant - February 2022

In February 2022, Delta Diagnostics and project partner SensUR Health obtained an MIT R&D grant from the Provincie Zuid-Holland to develop a Multiplexed Chronic Kidney Disease assay. This development will rely on a combination of the photonic biosensor technology of Delta Diagnostics and the Chronic Kidney Disease assays of SensUR Health to ultimately improve kidney patient care.